Last reviewed · How we verify
Latanoprost punctal plug
Latanoprost punctal plug is a Small molecule drug developed by Mati Therapeutics Inc.. It is currently in Phase 2 development.
Latanoprost punctal plug is used to treat Ocular Hypertension and Open-Angle Glaucoma, as indicated by ClinicalTrials.gov. The mechanism of action of Latanoprost is not explicitly stated in the provided facts, but according to ChEMBL, Latanoprost is a prostaglandin F2α analogue that lowers intraocular pressure.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Latanoprost punctal plug |
|---|---|
| Sponsor | Mati Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma (PHASE2)
- A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG (PHASE2)
- A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma (PHASE2)
- A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma (PHASE2)
- Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma (PHASE2)
- A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma (PHASE2)
- A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS) (PHASE2)
- A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Latanoprost punctal plug CI brief — competitive landscape report
- Latanoprost punctal plug updates RSS · CI watch RSS
- Mati Therapeutics Inc. portfolio CI
Frequently asked questions about Latanoprost punctal plug
What is Latanoprost punctal plug?
Who makes Latanoprost punctal plug?
What development phase is Latanoprost punctal plug in?
Related
- Manufacturer: Mati Therapeutics Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing